Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1995. Start Trial.
Date Value
June 30, 2026 -33.21M
March 31, 2026 -42.72M
December 31, 2025 -48.99M
September 30, 2025 -44.20M
June 30, 2025 -90.45M
March 31, 2025 -68.04M
December 31, 2024 -83.84M
September 30, 2024 -11.57M
June 30, 2024 -60.10M
March 31, 2024 -52.42M
December 31, 2023 -81.40M
September 30, 2023 71.51M
June 30, 2023 -24.22M
March 31, 2023 150.84M
December 31, 2022 -72.20M
September 30, 2022 -31.81M
June 30, 2022 -65.73M
March 31, 2022 -84.06M
December 31, 2021 -53.38M
September 30, 2021 -39.68M
June 30, 2021 117.69M
March 31, 2021 -55.23M
December 31, 2020 -90.08M
September 30, 2020 -34.93M
June 30, 2020 -44.72M
Date Value
March 31, 2020 -17.79M
December 31, 2019 -97.03M
September 30, 2019 -24.27M
June 30, 2019 -19.90M
March 31, 2019 -27.04M
December 31, 2018 -41.21M
September 30, 2018 222.53M
June 30, 2018 -62.83M
March 31, 2018 -0.952M
December 31, 2017 15.55M
September 30, 2017 -50.95M
June 30, 2017 -16.64M
March 31, 2017 -24.52M
December 31, 2016 -11.88M
September 30, 2016 242.16M
June 30, 2016 -32.05M
March 31, 2016 -19.54M
December 31, 2015 -13.37M
September 30, 2015 41.86M
June 30, 2015 -85.68M
March 31, 2015 -11.00M
December 31, 2014 25.48M
September 30, 2014 102.47M
June 30, 2014 -8.009M
March 31, 2014 -9.912M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Repligen Corp. -6.20M
BioLife Solutions, Inc. -3.594M
MindWalk Holdings Corp. 0.2478M
Maravai Lifesciences Holdings, Inc. -98.98M
MaxCyte, Inc. -1.42M